Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Pruritus Therapeutics Pipeline Review, H2 2016 - 25 Companies & 31 Molecules - Research and Markets

Research and Markets
Posted on: 04 Oct 16

Research and Markets has announced the addition of the "Pruritus - Pipeline Review, H2 2016" report to their offering.

'Pruritus - Pipeline Review, H2 2016'; Pruritus pipeline therapeutics constitutes close to 31 molecules. Out of which approximately 29 molecules are developed by Companies and remaining by the Universities/Institutes.

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

The report 'Pruritus - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Pruritus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type that are being developed by Companies/Universities.

It also reviews key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. Currently, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 13, 2, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Key Topics Covered:

1. Introduction

2. Pruritus Overview

3. Therapeutics Development

4. Pipeline Products for Pruritus - Overview

5. Pipeline Products for Pruritus - Comparative Analysis

6. Pruritus - Therapeutics under Development by Companies

7. Pruritus - Therapeutics under Investigation by Universities/Institutes

8. Pruritus Products Glance

9. Late Stage Products

10. Clinical Stage Products

11. Early Stage Products

12. Pruritus - Products under Development by Companies

13. Pruritus - Products under Investigation by Universities/Institutes

14. Pruritus - Companies Involved in Therapeutics Development

  • Albireo AB
  • Alveonix AG
  • Amorepacific Corporation
  • Asana BioSciences, LLC
  • Cara Therapeutics, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Creabilis SA
  • ELORAC, Inc.
  • Faes Farma, S.A.
  • GlaxoSmithKline Plc
  • Hydra Biosciences, Inc.
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • NeRRe Therapeutics Ltd
  • Nippon Shinyaku Co., Ltd.
  • Patara Pharma, Inc.
  • Phosphagenics Limited
  • RDD Pharma Ltd.
  • Sanwa Kagaku Kenkyusho Co., Ltd.
  • Shionogi & Co., Ltd.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Teikoku Pharma USA, Inc.
  • Tioga Pharmaceuticals, Inc.
  • Trevi Therapeutics, Inc.
  • Vanda Pharmaceuticals Inc.

For more information about this report visit http://www.researchandmarkets.com/research/zsn43q/pruritus

View source version on businesswire.com: http://www.businesswire.com/news/home/20161004006104/en/

Business Wire
www.businesswire.com

Last updated on: 04/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.